Skip To Main Content
Carlos Cuenca-Barrales on Muck Rack

Carlos Cuenca-Barrales

As seen in: Wiley Online Library, MDPI, Dialnet - Universidad de La Rioja, Journal of The American Academy of Dermatology (JAAD)
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Carlos

Contact Carlos, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Severity and Therapeutic Decisions Based on Lesion Location in Patients With Hidradenitis Suppurativa

|
By Daniel Muñoz-Barba, Francisco Javier Leon-Pérez, Carlos Cuenca-Barrales, Salvador Arias-Santiago
| Wiley Online Library Verified
Background Hidradenitis suppurativa (HS) is a chronic inflammatory disease for which several phenotypic classifications have been proposed in recent years to optimize medical care. The aim of this study was to define a new classification of HS based on the anatomical distribution of lesions, serving as a tool for therapeutic decision-making.
Open in Who Shared Issue with article?

Therapeutic burden in hidradenitis suppurativa: a cross‐sectional study of 557 patients

|
By Sofía Haselgruber, Daniel Muñoz-Barba, Carlos Cuenca-Barrales, Francisco Javier Leon-Pérez
| Wiley Online Library Verified
Introduction Hidradenitis suppurativa (HS) remains a significant challenge for dermatologists, despite recent advances in its study and treatment. Managing HS is complex due to the variability in patient responses and the disease's unpredictable nature, and it often requires a multidisciplinary approach.1, 2 Yet, many patients are refractory to available treatments, persisting with inadequate control of inflammation and symptoms.
Open in Who Shared Issue with article?

Certolizumab pegol: ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave?

|
By Ricardo Ruiz Villaverde, Carlos Cuenca-Barrales, Luis Rodríguez Verified, Luis Rodríguez, Ruiz Villaverde
| Dialnet - Universidad de La Rioja
Certolizumab pegol: ¿un nuevo anti-TNF en el tratamiento de la psoriasis moderada-grave? Ruiz Villaverde, R. [1] ; Cuenca Barrales, C. [1] ; Salvador Rodriguez, L. [1] ; Ruiz Carrascosa, J.C. [1] [1] Unidad de Dermatología, Complejo Hospitalario de Granada, Granada, España Localización: Piel: Formación continua en dermatología, ISSN 0213-9251, Vol. 32, Nº. 10 (DICIEMBRE), 2017, págs.
Open in Who Shared Issue with article?
See all 8 licensed articles (10 Total)